3.16 USD
▲+0.06+10.49%
盘后 2.85 -0.34%
2026-08-03
市值
$74.11M
市盈率
—
EPS
-2.42
股息率
—
52 周区间
2.66 – 16.00
成交量
692.41K
Beta
1.79
目标价
20.00
52W 低 2.6652W 高 16.00
价格走势
公司简介
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targe...